Amylyx Pharmaceuticals (NASDAQ: AMLX) provided pre-launch commercial-readiness detail Tuesday September 1, 2026 as the company continues to advance toward NDA submission for avexitide (exendin-9-39, a GLP-1 receptor antagonist peptide) in post-bariatric hypoglycemia (PBH) following the August 18 Phase 3 LUCIDITY primary-endpoint hit (55% reduction in composite Level 2/3 hypoglycemic events, p=0.000003). Target NDA submission end of 2026; commercial launch preparation continues on schedule; and the company will use the upsized $500.2 million August 21 public offering to fund launch operations plus AMX0318 (long-acting follow-on peptide) IND-enabling studies. The Priority Review Voucher regime granted Arrowhead $215 million for plozasiran continues to shape the commercial economics of first-in-class peptide approvals in rare metabolic indications, and Amylyx is expected to be eligible if avexitide receives Breakthrough Therapy designation.
BioMarin Pharmaceutical (NASDAQ: BMRN) hosts its Q2 2026 financial results conference call and webcast Thursday August 6, 2026 at 4:30 PM ET. Analyst focus areas: Voxzogo (vosoritide) commercial trajectory in achondroplasia (Voxzogo is a C-type natriuretic peptide analog administered by daily subcutaneous injection, making it a substantive peptide franchise for the site's coverage); ROCTAVIAN (valoctocogene roxaparvovec) hemophilia A AAV gene therapy commercial ramp and payer coverage; Palynziq (pegvaliase-pqpz) for phenylketonuria (PKU) revenue trajectory; and the broader rare-disease enzyme replacement franchise including VIMIZIM (elosulfase alfa), Naglazyme (galsulfase), and Aldurazyme (laronidase). BioMarin has been transitioning its commercial focus from the mature enzyme replacement franchise toward newer growth drivers (Voxzogo and ROCTAVIAN) with analyst attention on the balance of growth-portfolio contribution versus legacy-franchise stability. Amylyx Pharmaceuticals (NASDAQ: AMLX) also reports Q2 2026 results Thursday August 6 at 8:00 AM ET, with focus on the amyotrophic lateral sclerosis (ALS) pipeline following the March 2024 US withdrawal of Relyvrio and pipeline reprioritization to progressive supranuclear palsy (PSP) and other rare neurodegenerative indications. Tarsus Pharmaceuticals (NASDAQ: TARS) reports at 8:00 AM ET.
Amylyx Pharmaceuticals on May 5 launched a U.S. Expanded Access Program (EAP) for up to 250 adults with post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass surgery. The investigational compound, avexitide, is a first-in-class peptide GLP-1 *receptor antagonist* — designed to bind GLP-1 receptors on pancreatic islet beta cells and block the exaggerated GLP-1-driven insulin response characteristic of PBH, reducing inappropriate insulin secretion and stabilizing blood glucose. Avexitide carries FDA Breakthrough Therapy Designation for both PBH and congenital hyperinsulinism, plus Orphan Drug Designation. Topline data from the pivotal Phase 3 LUCIDITY trial are anticipated in Q3 2026. The program inverts the standard GLP-1 narrative — for this population, GLP-1 signaling is the problem.